ライフサイエンスコーパス: human immunodeficiency virus type 2

1 ency virus, termed SIVsm, which gave rise to human immunodeficiency virus type 2.

2 Vesicular stomatitis virus, human immunodeficiency virus type 2, and human foamy vir

3 ch as infection with hepatitis B or C and/or human immunodeficiency virus, type 2 diabetes, hemochrom

4 Human immunodeficiency virus type 2 (HIV-2) and a simian

5 for M. mulatta and M. nemestrina, restricts human immunodeficiency virus type 2 (HIV-2) and feline i

6 (SIVsmm) is recognized as the progenitor of human immunodeficiency virus type 2 (HIV-2) and has been

7 The vpx gene products of human immunodeficiency virus type 2 (HIV-2) and of the c

8 Vpx is a virion-associated protein of human immunodeficiency virus type 2 (HIV-2) and simian i

9 e source virus of pathogenic infections with human immunodeficiency virus type 2 (HIV-2) and SIV(mac)

10 Human immunodeficiency virus type 2 (HIV-2) and some sim

11 The envelope (Env) protein of human immunodeficiency virus type 2 (HIV-2) and the HIV-

12 Envelope glycoproteins (Envs) of human immunodeficiency virus type 2 (HIV-2) are frequent

13 Human immunodeficiency virus type 2 (HIV-2) causes AIDS,

14 sites for the ets family member Elf-1 in the human immunodeficiency virus type 2 (HIV-2) enhancer.

15 Human immunodeficiency virus type 2 (HIV-2) gene express

16 Human immunodeficiency virus type 2 (HIV-2) has been rep

17 nvelope glycoprotein of the ROD10 isolate of human immunodeficiency virus type 2 (HIV-2) has the abil

18 The human immunodeficiency virus type 2 (HIV-2) IN has been

19 Human immunodeficiency virus type 2 (HIV-2) infection is

20 Human immunodeficiency virus type 2 (HIV-2) infection is

21 Human immunodeficiency virus type 2 (HIV-2) infection is

22 Studies have shown that human immunodeficiency virus type 2 (HIV-2) is less path

23 Human immunodeficiency virus type 2 (HIV-2) is less path

24 Epidemiological studies have shown that human immunodeficiency virus type 2 (HIV-2) is markedly

25 The packaging signal (psi) of human immunodeficiency virus type 2 (HIV-2) is present i

26 Human immunodeficiency virus type 2 (HIV-2) is the resul

27 Groups of macaques infected with human immunodeficiency virus type 2 (HIV-2) isolate (eit

28 termines the cellular tropism of two related human immunodeficiency virus type 2 (HIV-2) isolates and

29 inding, the envelope glycoprotein of certain human immunodeficiency virus type 2 (HIV-2) isolates, in

30 egan to suggest that the TAR region from the human immunodeficiency virus type 2 (HIV-2) may suppress

31 e inoculated with an infectious, apathogenic human immunodeficiency virus type 2 (HIV-2) molecular cl

32 that the glycoprotein cytoplasmic domains of human immunodeficiency virus type 2 (HIV-2) or simian im

33 Human immunodeficiency virus type 2 (HIV-2) originated f

34 It has been proposed that human immunodeficiency virus type 2 (HIV-2) originated f

35 Considering human immunodeficiency virus type 2 (HIV-2) phenotypic d

36 the psi encapsidation signal is critical for human immunodeficiency virus type 2 (HIV-2) replication

37 an immunodeficiency virus type 1 (HIV-1) and human immunodeficiency virus type 2 (HIV-2) reverse tran

38 In vitro, dimerization of human immunodeficiency virus type 2 (HIV-2) RNA occurs b

39 , simian immunodeficiency viruses (SIV), and human immunodeficiency virus type 2 (HIV-2) to enter per

40 for simian immunodeficiency virus (SIV) and human immunodeficiency virus type 2 (HIV-2) to inhibit v

41 nction of preintegration complexes (PICs) of human immunodeficiency virus type 2 (HIV-2) to investiga

42 f CCR5 inhibitors requires a tool to predict human immunodeficiency virus type 2 (HIV-2) tropism, as

43 Incorporation of Vpx into human immunodeficiency virus type 2 (HIV-2) virus-like p

44 Human immunodeficiency virus type 2 (HIV-2) Vpx is requi

45 ted to infection by some primary isolates of human immunodeficiency virus type 2 (HIV-2), although ea

46 Most simian immunodeficiency virus (SIV), human immunodeficiency virus type 2 (HIV-2), and HIV-1 i

47 4-independent simian immunodeficiency virus, human immunodeficiency virus type 2 (HIV-2), and laborat

48 Human immunodeficiency virus type 2 (HIV-2), like other

49 ty mangabeys harbor divergent members of the human immunodeficiency virus type 2 (HIV-2)-sooty mangab

50 tegravir has shown in vitro activity against human immunodeficiency virus type 2 (HIV-2).

51 However, for human immunodeficiency virus type-2 (HTLV-2) IN, the rep

52 ug has been targeted specifically for HIV-2 (human immunodeficiency virus type 2) infection despite i